



Senate

General Assembly

File No. 285

February Session, 2012

Senate Bill No. 436

Senate, April 5, 2012

The Committee on Public Health reported through SEN. GERRATANA of the 6th Dist., Chairperson of the Committee on the part of the Senate, that the bill ought to pass.

AN ACT CONCERNING PRESCRIPTION DRUG MONITORING.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 21a-317 of the general statutes is repealed and the
2 following is substituted in lieu thereof (*Effective October 1, 2012*):

3 Every practitioner who distributes, administers or dispenses any
4 controlled substance or who proposes to engage in distributing,
5 prescribing, administering or dispensing any controlled substance
6 within this state shall (1) obtain a certificate of registration issued by
7 the Commissioner of Consumer Protection in accordance with the
8 provisions of this chapter, and (2) register for access to the electronic
9 prescription drug monitoring program, established in accordance with
10 subsection (j) of section 21a-254, in the manner prescribed by the
11 commissioner.

This act shall take effect as follows and shall amend the following sections:

Section 1	<i>October 1, 2012</i>	21a-317
-----------	------------------------	---------

PH *Joint Favorable*

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note***State Impact:*** None***Municipal Impact:*** None***Explanation***

The bill results in no fiscal impact to the Department of Consumer Protection as the agency already has the prescription drug monitoring program in place and the bill only requires additional providers to register.

The Out Years***State Impact:*** None***Municipal Impact:*** None

OLR Bill Analysis**SB 436*****AN ACT CONCERNING PRESCRIPTION DRUG MONITORING.*****SUMMARY:**

This bill requires people or institutions that must register with the Department of Consumer Protection (DCP) as controlled substance practitioners to also register for access to DCP's electronic prescription drug monitoring program (see BACKGROUND). They must do so in the manner the DCP commissioner prescribes.

The bill applies to practitioners distributing, administering, or dispensing controlled substances in Connecticut, or proposing to distribute, prescribe, administer, or dispense controlled substances in this state. By law, such practitioners must register with DCP as controlled substance practitioners.

For this purpose, practitioners are: physicians; dentists; veterinarians; podiatrists; optometrists; physician assistants; advanced practice registered nurses; nurse-midwives; scientific investigators; hospitals; or other people or institutions licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or administer a controlled substance in the course of professional practice or research in the state.

EFFECTIVE DATE: October 1, 2012

BACKGROUND***Electronic Prescription Drug Monitoring Program***

DCP's electronic prescription drug monitoring program collects and maintains in a central database prescription data for Schedule II through Schedule V controlled substances dispensed by pharmacies and outpatient pharmacies in hospitals or institutions. Information in

the database is available to prescribing practitioners and pharmacists in the treatment of their patients.

Related Bill

sHB 5056 (File 92), reported favorably by the General Law Committee, expands the electronic prescription drug monitoring program to include (1) out-of-state pharmacies that send drugs into the state and (2) any other drug dispensing practitioner. It also allows the DCP commissioner to identify additional products to be included in the program.

COMMITTEE ACTION

Public Health Committee

Joint Favorable

Yea 24 Nay 0 (03/23/2012)